LEO Pharma and Elektrofi expand partnership to co-develop new antibodies with the aim of achieving improvements in drug delivery within dermatology
Ballerup, April 9, 2019: LEO Pharma A/S, a global leader in medical dermatology and Elektrofi, a Boston- based biotechnology company focused on drug formulation and delivery innovations, today announced an expansion of the two companies’ partnership agreement (signed in 2017) to further include antibodies from LEO Pharma’s pipeline with the aim of achieving improvements in drug delivery within dermatology.
As part of the agreement LEO Pharma and Elektrofi will initially co-develop two specific anti-bodies. The agreement includes an option to a pre-negotiated license for the potentially improved antibodies in the pre-clinical and clinical stage. LEO Pharma and Elektrofi will work closely together in an alliance to enable a lower injection volume for subcutaneous administration and, in turn, enable novel formulations and better convenience for patients.
“At LEO Pharma we are working constantly to find innovative ways to help people with skin diseases and improve their quality of life. Together with Elektrofi, we hope to find new, more convenient solutions for drug delivery, which potentially will be of benefit to patients,” said Kim Kjøller, executive Vice President, Research & Development, LEO Pharma.
“We are excited to further our partnership with LEO Pharma, who we consider to be a leader in patient centric innovation. This flagship deal for our growing company is an exciting consummation of a close partnership over the last 2 years. The biopharma industry’s continued shift to subcutaneous administration is a reflection of patients’ demand for convenience. Elektrofi is thrilled to utilize its technology with LEO Pharma to improve patients’ lives,” said Jason Norris, Cofounder, Elektrofi.
About Elektrofi’s technology: Elektrofi leverages its microparticle suspension formulation technology (ElektrojectTM) to enable syringe-compatible injections of high-dose antibody therapeutics. Most antibody solutions are unusable in syringes at high concentrations due to concentration associated syringe forces that exceed human ability, leaving drug developers to either increase dose frequency or administer prolonged, large-volume infusions. ElektrojectTM suspensions enable clinicians and patients to administer high doses of antibody therapies in a relatively small volume within seconds in addition to providing improved product stability at full quality.
Jason Norris, Cofounder
LEO Pharma A/S
Trine Juul Wengel
Tel.: +45 20732037
Information om LEO Pharma
Elektrofi is a biotechnology company headquartered in Boston, MA, USA working on transforming the delivery of biologics. We envision a patient-centric future where all protein therapeutics can be conveniently administered to patients in small-volume syringe injections instead of large-volume intravenous infusions or frequent injections. Elektrofi’s gentle platform technology, ElektrojectTM, enables the transformation to high-dose subcutaneous delivery without compromise on product quality for a wide-range of biologics. For more information, please visit www.elektrofi.com or send a message to
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.
For more information, go to: www.linkedin.com/company/leo-pharma or www.leo-pharma.com
Følg pressemeddelelser fra LEO Pharma
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra LEO Pharma
LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825 a Novel Atopic Dermatitis and Asthma Drug Candidate15.4.2020 07:45:16 CEST | Press release
BALLERUP, Denmark, April 15, 2020 – LEO Pharma A/S, a global leader in medical dermatology, today announced that is has signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan, TPEx: 4743) and Microbio Shanghai (China) covering the development and commercialization of the novel Atopic Dermatitis (AD) and Allergic Asthma drug candidate, FB825.
LEO Pharma Group completes divestment of Emollients and Proctology Portfolio to Karo Pharma2.3.2020 12:05:26 CET | Press release
Ballerup, DENMARK, March 2, 2020 – LEO Pharma today announced that the divestment of its emollients and proctology portfolio to Karo Pharma for 90 MEUR has been completed. The initial agreement with Karo Pharma was announced on December 23, 2019 and approved by relevant competition authorities on February 20, 2020. This divestment marks an important step for LEO Pharma towards strategically aligning its portfolio and increasing focus on innovation and dermatology. The divested products include four anti-hemorrhoid products (Sheriproct®, Doloproct®, Neriproct® and Ultraproct®) and six dermatology products, mainly over-the-counter products (Ultrabas®, Ultralip®, Ultraphil®, Ultrasicc®, Neribas® and Ultralan®).
With topline growth of 7% in 2019, margin improvements and pipeline success, LEO Pharma paves the way for an ambitious future27.2.2020 21:00:00 CET | Press release
LEO Pharma helped 92 million patients and reached revenue of DKK 10,805 million in 2019 - 2019 revenue up by 4% to DKK 10,805 million – with a strong fourth quarter demonstrating further momentum. This was driven by strong performances of Enstilar®, Kyntheum® and the prescription portfolio acquired from Bayer. - Underlying revenue grew by 7%. This excludes currency effects, divestments of non-core business to Karo Pharma and other one-time effects. - Revenue in region Europe+ grew 5% to DKK 6,840 million, due to Enstilar®, Kyntheum® and the acquired Bayer portfolio. - Sales in region International grew 12% to DKK 3,117 million, due to the acquired Bayer portfolio. - US sales declined 22% to DKK 848 million, due to generic competition and price pressure. We continue to see the US as a key growth driver in the future and are stepping up the launch preparations for tralokinumab accordingly. Established business remains the backbone with continued growth and improved profitability - Toplin
LEO Pharma Signs Agreement to Divest Emollients and Proctology Portfolio to Karo Pharma23.12.2019 12:10:00 CET | Press release
Ballerup, DENMARK, December 23, 2019 – Today, LEO Pharma announced the sale of 10 products to Karo Pharma AB for 90 MEUR. The divested portfolio isnon-core to LEO Pharma’s business, and was part of the portfolio acquired from Bayer in July 2019. “This divestment is an important step for LEO Pharma towards strategically aligning our portfolio and increasing focus on innovation and dermatology. This well-established portfolio will be better served by Karo Pharma and its team,” said Anders Kronborg, Chief Financial Officer, LEO Pharma. The product portfolio includes four anti-haemorrhoid products (Sheriproct®, Doloproct®, Neriproct® and Ultraproct®) and six dermatology, mainly over-the-counter products (Ultrabas®, Ultralip®, Ultraphil®, Ultrasicc®, Neribas® and Ultralan®). Karo Pharma is a fast-growing specialty pharma company that develops and markets products to physicians, pharmacies and directly to healthcare providers. The company is listed on the Swedish stock exchange, Nasdaq Stock
LEO Pharma announces positive top-line results for tralokinumab from three Phase 3 studies in adult patients with moderate-to-severe AD11.12.2019 08:05:00 CET | Press release
BALLERUP, Denmark, December 11, 2019 – LEO Pharma A/S, a global leader in medical dermatology, today announced that tralokinumab – an investigational, fully human monoclonal antibody that specifically neutralizes the interleukin-13 (IL-13) cytokine – met all primary and secondary endpoints in its three pivotal Phase 3 studies (ECZTRA 1-3) for the treatment of moderate-to-severe atopic dermatitis (AD) in adults. During the studies, the overall adverse event rate was comparable between tralokinumab and placebo. IL-13 is a key driver of the type 2 inflammation that plays a major role in AD,(1) which is the most common inflammatory skin disease in the developed world,(2) affecting up to five percent of adults across the United States, Canada, Europe and Japan.(3) AD can have a significant, negative impact on patients’ well-being, primarily due to distressing itch, sleep deprivation and social stigmatization due to visible lesions.(4) “In its moderate-to-severe form, AD can cause unbearable
LEO Pharma and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device4.12.2019 09:03:00 CET | Press release
Ballerup, DENMARK and Cambridge, MA, USA – December 4, 2019 – LEO Pharma A/S and Portal Instruments today announced a global collaboration and license agreement to develop Portal’s innovative needle-free drug delivery system for use in combination with LEO Pharma’s portfolio of investigational and approved medicines.
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum